Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. (OTLK) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
otlk · stock forecast · 14 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Buy
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1.00
Consensus
$1.00
+38.5% upside
Low
$1.00
Median: $1 · Last Close: $0.72
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.72 | ↑ 0.00% |
1-day model range: $0.71–$0.74. Peak: $0.74 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · OTLK · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-18 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2026-03-11 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-02-18 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2026-02-18 | Chardan Capital | Maintains | Neutral→Neutral |
| 2026-01-05 | Chardan Capital | Maintains | Neutral→Neutral |
| 2026-01-02 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-12-22 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-09-30 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-09-22 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-08-29 | Guggenheim | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on Outlook Therapeutics, Inc. (OTLK) stock. Of the recent 60 rating actions, 5 were upgrades and 11 were downgrades. 14 analysts currently cover OTLK.
Analyst Recommendation Trends
OTLK analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$16M
↓ 29.9% YoY
Revenue Next Year
$47M
↑ 193.4% YoY
EPS This Year
$-0.51
EPS Next Year
$-0.26
↓ 48.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast OTLK EPS of $-0.51 for the current fiscal year, based on estimates from 2 analysts. The OTLK revenue forecast is $16M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The OTLK stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus OTLK price target is $1.00 (+38.5% upside), with an analyst consensus of Buy.
The OTLK short-term stock prediction for tomorrow is $0.72 (+0.00%).
Outlook Therapeutics, Inc. trades on NASDAQ under the ticker OTLK. The OTLK stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
OTLK forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month OTLK price target is $1.00, with a high forecast of $1.00 and a low of $1.00. The median price target is shown in the chart above when available. This implies +38.5% potential upside from the current price of $0.72.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.